BioSpace News Archive

Monteris Medical announced today that the first patient has been enrolled in its REMASTer (Recurrent Brain Metastases After Stereotactic Radiosurgery [SRS] Trial) clinical trial.

Agadia Systems, Inc. (Agadia), a recognized healthcare technology solution provider for over 50 of the nation’s leading Health Plans & PBMs, is announcing an integration with language solutions provider, CQ fluency, to provide translation services within Agadia’s prior authorization solution, PAHub.

Pyrogens are substances that lead to causing fever after administration of an injection. Rise in the body temperature and body ache are some of the prominent reactions that are caused because of injection of these harmful pyrogens in the human body.

The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest early-phase drug development program for brain cancer, announced its initiation of a ‘Liquid Biopsy’ program to obtain real-time insights into how a patient’s brain tumor is responding to experimental treatment.

Assertio Holdings, Inc. announced that Dan Peisert, CEO, will host investor meetings September 14, 2022 as part of the Lake Street Capital Markets Best Ideas Growth Conference, taking place at The Yale Club in New York City.

Neovii Pharmaceuticals AG and Shanghai Fosun Pharmaceutical Industry Development Co. Ltd have entered into an exclusive agreement, under which Neovii has granted Fosun Pharma Industry an exclusive license to develop and commercialize Neovii’s Grafalon® in Chinese Mainland, Hong Kong SAR, Macau SAR and Taiwan region.

Vivalink, a leading provider of digital healthcare solutions, today announces the results of its survey of cardiac rehabilitation clinicians and their insights into the current landscape of remote patient monitoring (RPM).

Medical Microinstruments, Inc. (MMI), a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced the launch of its new Supermicro NanoWrist® instruments for use with the Symani® Surgical System, developed specifically to address the challenges of microsurgery.

CuraSen Therapeutics, Inc., a clinical-stage company developing small molecule therapies to treat neurodegenerative disease, announced that it has begun dosing patients in a Phase 2a clinical trial with CST-2032, a novel, oral beta-2 adrenoceptor (β2-AR) agonist.

Iterum Therapeutics plc announced that Corey Fishman, Chief Executive Officer, and Judy Matthews, Chief Financial Officer, will provide a company overview and business update at the H.C. Wainwright 24th Annual Hybrid Global Investment Conference at 12:00pm on Wednesday, September 14, 2022.